Post

New research · Hematology
Transplantation and cellular therapy · 23h
Cohort studyTransplantation and cellular therapy · 2026

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Hadeel Jazieh, Abedalrahman Almashayekh, J Curran Henson … Nishank Jain
Read paper
HematologyCohort study

Acute kidney injury is associated with increased mortality in CAR-T therapy recipients.

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality.

Hadeel Jazieh et al. · Transplantation and cellular therapy · 2026
Background

Chimeric antigen receptor T-cell (CAR-T) therapy is a breakthrough in hematologic malignancies but carries risks, including acute kidney injury (AKI).

Methods

This retrospective study analyzed 186 patients treated with CAR-T therapy, assessing AKI incidence, timing, severity, and associated risk factors within 100 days post-infusion of CAR-T product.

n = 186 patients
Results

sudden kidney damage meant over twice the risk of death for CAR-T recipients

HR 2.59 (95% CI 1.33 to 5.04)
null = 11.335.04
CI excludes the null - significant
More results

Among 186 patients (103 with multiple myeloma (MM), 75 with non-Hodgkin Lymphoma (NHL), and 8 with leukemia), 34% developed AKI (95% CI: 27%-40.7%) with similar incidence by cancer type.

Overall CRS incidence was 82.8% (95% CI: 76.7% to 87.5%) , and 35.1% had AKI although no statistical significance found when compared to those without CRS.

More results

Higher grades of CRS had higher incidence of AKI (Grade 1 = 33.9%; Grade 2 = 37.9%, Grade 3 = 42.9%, P = 0.83) Most AKI episodes were Grade 1 (69.8%) and reversible; 71.4% recovered baseline kidney function, while 28.6% did not, two died within 100 days, 1 required dialysis.

“
Conclusion · 1 of 2

AKI is a frequent and early complication of CAR-T therapy, particularly among African American patients, older individuals, those with CKD and prior history of AKI.

Conclusion · 2 of 2

While most cases are mild and reversible, identifying high-risk patients may enhance monitoring, supportive care, and early intervention.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Study
92.3%
Share of treated patients whose lymphoma shrank or cleared after treatment
Randomized Trial
60%
Cumulative mortality was 60% with beta-glucan, reduced from 100% in untreated fish.
Study
30%
About 30% of peptides from multiple myeloma cell lines stimulated CD8+ T-cell responses.
AI / Informatics
C-index = 96.0%
The model accurately predicted when initial leukemia treatment would not work
Cohort Study
97.30%
The AI model correctly identified aplastic anemia or myelodysplastic syndromes 97.30% of the time.
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
OR 3.8
Each additional low lab value associated with 3.8 times higher odds of Multisystem Inflammatory Syndrome in Children.
Cohort Study
30% higher risk
increased risk of new low blood cell counts per 0.1 g/L C3 decrease